PMID- 10416590
OWN - NLM
STAT- MEDLINE
DCOM- 19990812
LR  - 20201222
IS  - 0008-5472 (Print)
IS  - 0008-5472 (Linking)
VI  - 59
IP  - 14
DP  - 1999 Jul 15
TI  - Biodistribution and vaccine efficiency of murine dendritic cells are dependent on 
      the route of administration.
PG  - 3340-5
AB  - Dendritic cells (DCs) are professional antigen-presenting cells, well equipped to 
      initiate an immune response. Currently, tumor antigen-derived peptide loaded DCs 
      are used in clinical vaccination in cancer patients. However, the optimal dose 
      and route of administration of a DC vaccine still remain to be determined. Using 
      indium-111-labeled DCs, we investigated whether the route of administration does 
      affect the biodistribution of DCs in lymphoid organs and whether it influences 
      the outcome of DC vaccination in the B16 mouse melanoma tumor model. The results 
      demonstrate that i.v. injected DCs mainly accumulate in the spleen, whereas s.c. 
      injected DCs preferentially home to the T-cell areas of the draining lymph nodes. 
      Using tyrosinase-related protein-2-derived peptide-loaded DC vaccination in a 
      fully autologous B16 melanoma tumor model, we observed a delay in tumor growth, 
      improved survival as well as increased antitumor cytotoxic T-cell reactivity 
      after s.c. vaccination as compared to i.v. vaccination. These data demonstrate 
      that optimal induction of antitumor reactivity against the autologous melanocyte 
      differentiation antigen tyrosinase-related protein-2-derived peptide occurs after 
      s.c. vaccination and correlates with the preferential accumulation of DCs in the 
      T-cell areas of lymph nodes.
FAU - Eggert, A A
AU  - Eggert AA
AD  - Tumor Immunology Laboratory, University Hospital Nijmegen St. Radboud, The 
      Netherlands.
FAU - Schreurs, M W
AU  - Schreurs MW
FAU - Boerman, O C
AU  - Boerman OC
FAU - Oyen, W J
AU  - Oyen WJ
FAU - de Boer, A J
AU  - de Boer AJ
FAU - Punt, C J
AU  - Punt CJ
FAU - Figdor, C G
AU  - Figdor CG
FAU - Adema, G J
AU  - Adema GJ
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Cancer Res
JT  - Cancer research
JID - 2984705R
RN  - 0 (Antigens, Neoplasm)
RN  - 0 (Cancer Vaccines)
RN  - 0 (Indium Radioisotopes)
RN  - 0 (Peptide Fragments)
RN  - EC 5.3.- (Intramolecular Oxidoreductases)
RN  - EC 5.3.3.12 (dopachrome isomerase)
SB  - IM
MH  - Animals
MH  - Antigens, Neoplasm/administration & dosage/*immunology
MH  - Cancer Vaccines/*administration & dosage/pharmacokinetics/therapeutic use
MH  - Cell Movement
MH  - Dendritic Cells/*transplantation
MH  - Immunization Schedule
MH  - *Immunotherapy, Active
MH  - Indium Radioisotopes
MH  - Injections, Intravenous
MH  - Injections, Subcutaneous
MH  - Intramolecular Oxidoreductases/administration & dosage/*immunology
MH  - Lymph Nodes/chemistry
MH  - Lymphoid Tissue/chemistry
MH  - Male
MH  - Melanoma, Experimental/immunology/metabolism/pathology/*therapy
MH  - Mice
MH  - Mice, Inbred C57BL
MH  - Neoplasm Transplantation
MH  - Peptide Fragments/administration & dosage/*immunology
MH  - Specific Pathogen-Free Organisms
MH  - Spleen/chemistry
MH  - T-Lymphocytes, Cytotoxic/immunology
EDAT- 1999/07/23 00:00
MHDA- 1999/07/23 00:01
CRDT- 1999/07/23 00:00
PHST- 1999/07/23 00:00 [pubmed]
PHST- 1999/07/23 00:01 [medline]
PHST- 1999/07/23 00:00 [entrez]
PST - ppublish
SO  - Cancer Res. 1999 Jul 15;59(14):3340-5.